28 Jan TOPPLE study for adults with type 1 diabetes who live in the Seattle area
Patients ages 18 – 45 with type 1 diabetes diagnosed in the past four years have an opportunity to participate in a TrialNet study that is testing the safety of a new treatment, NNC0361-0041. The treatment is a plasmid vector designed to transfer DNA into cells, where it can communicate with the immune system.
Earlier studies in the lab show this treatment might retrain the immune system to stop attacking insulin-producing beta cells.
While plasmids are small circular pieces of DNA, they do not change your DNA. They are currently being studied in many clinical trials for other conditions.
You may be eligible to participate if you:
• have been diagnosed with type 1 diabetes within the past 48 months (four years),
• are 18 – 45 years of age,
• live in the Seattle area.
Additional Study Details
Full Study Title
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 (TOPPLE T1D)
Carla Greenbaum, MD
Accepts Healthy Volunteers?
Benaroya Research Institute
1201 Ninth Ave
Seattle, Washington 98101